Characterization of hereditary tumor risk in individuals with SDHA germline variants. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...
Immunome Inc. IMNM said the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application for varegacestat, ...
This review will appear in the June issue of Evidence-Based Oncology. Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that arise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results